Skip to main content

Table 4 Associated mutations noted on NGS along with response data

From: HER2/neu-directed therapy for biliary tract cancer

Cancer type HER2/neu status Associated mutations Best response Agent PFS (weeks) OS (weeks)
Cholangioca Mutation (V777L) FGFR3, TP53 SD Trastuzumab 19 29
Cholangioca Amplification BAP1, CDKN2A, KDM6A, PBRM1, SETD2 PD Trastuzumab 14 25
Cholangioca Mutation (S310F) KRAS, MYC, TP53, EZH2, MSH6 PD Trastuzumab 7 7
Cholangioca Amplification   PD Trastuzumab 6 8
Cholangioca Amplification   PD Trastuzumab 10 12
Gallbladder cancer Amplification PIK3CA, CDKN2A/B, TP53, ZNF703 MR Lapatinib 15 19
Gallbladder cancer Amplification TP53 PR Trastuzumab >92 >92
Gallbladder cancer Amplification NRAS, PIK3CA, RB1,PTEN, TP53 PR Trastuzumab >40 >62
Gallbladder cancer Amplification   PR Trastuzumab 168 178
Gallbladder cancer Amplification   PR Trastuzumab 38 113
Gallbladder cancer Amplification FGFR3-TACC3 fusion, TP53, CCNE1, MCL1, MYC SD Trastuzumab + pertuzumab +8 +8
  1. SD stable disease, PD progressive disease, MR mixed response, PR partial response
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us